Researchers from the University of Technology Mara (UiTM), Malaysia, the Malays have mapped the genome, an important breakthrough that is expected to generate billions of ringgit from the pharmaceutical and biotechnology industries.
Chief Executive Officer of the Malaysian Biotech Corporation (BiotechCorp) Mohd Kamal stated Nazlee genome map could result in "approximately RM2 billion per year" or about Rp 5, 7 trillion.
Leap science paves the way for special treatment or personal in Southeast Asia. As is known, the citizens of Malaysia is a composition that represents a number of neighboring countries like Thailand, Indonesia and the Philippines.
"Ethnic Malay population numbered about 200 million people in Southeast Asia - Malaysia, Indonesia, Thailand and the Philippines. The region is seen as a lucrative market because people are more prosperous condition," said Nazlee reported by the New Straits Times.
"The genome of Malaysia is very valuable to drug companies in developing personalized medicine, which is more effective that can be targeted to people who have the same genetic footprint."
Nazlee explained, most drugs are developed now actually does not fit with the local population because it is designed for the European market.
This research was conducted over three generations of Malay families using techniques similar to those used to identify genomic Caucasians and Japanese. The project is fully financed worth RM150.000 UiTM using equipment and technology BiotechCorp since June 2010 and was completed seven months later.
While the lead researcher Prof Salleh Mohd Zaki said the Malay genome research will be included in the Human Genome Project database that is accessible to interested researchers. He also revealed, Minister of Higher Education has approved the grant RM8 million for continued research on the population of Orang Asli, indigenous peoples of Malaysia.
The results of this discovery was announced Deputy Prime Minister of Malaysia, Tan Sri Muhyiddin at UiTM campus on Tuesday, December 27 last. "These findings encourage the development, particularly biotechnology as a potential high-income industry," said Muhyiddin.
He conveyed, BiotechCorp, the country's lead agency for the biotechnology, has facilitated 207 BioNexus-status companies, with an investment of RM2, 118 billion, of which three per cent were enrolled in the Malaysian stock exchange, Australia and Europe.
Artikel keren lainnya: